前沿生物：公司在布局小核酸管线的同时，始终将递送技术的自主研发作为核心能力建设重点

Core Viewpoint - The company emphasizes the importance of independent research and development of delivery technology while expanding its small nucleic acid pipeline [1] Group 1: Delivery Technology - The company has applied for a patent for a delivery system and has completed its public disclosure [1] - Research and exploration of delivery technology are being conducted in other tissue areas with rich targets [1] - Future focus will be on small nucleic acid delivery technology, particularly extrahepatic delivery technology [1] Group 2: R&D Investment - The company plans to continuously increase R&D investment to build long-term and sustainable technological competitiveness through innovation [1]